Chemotherapy as a possible trigger for the myocardial lipomatosis development

Avagimyan, Ashot; Mkrtchyan, L. G.; Конончук, Н. Б.; Kakturskiy, L. V.; Agati, Luciano

doi:10.18705/1607-419x-2021-27-6-706-712

Cited by 10 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…all manipulations were carried out following the European Convention's provisions for the при усредненных кумулятивных дозах развивается целый спектр кардиологической симптоматики. Нами подробно описаны клинические случаи развития фибрилляции предсердий (ФП) [6], липоматоза миокарда [7], микроваскулярной стенокардии [8] и атерогенной гипердислипидемии [9]. В связи с вышеотмеченным было решено исследовать кардиотоксический и проатерогенный потенциал АС-режима химиотерапии.…”

Section: Adherence To Ethical Standardsunclassified

Trimetazidine as a modifier of doxorubicin+cyclophosphamideinduced hyperdyslipidemia

Avagimyan

Kakturskiy

2022

SJCEM

Self Cite

View full text Add to dashboard Cite

Aim. The present work aimed at studying the proatherogenic potential of doxorubicin-cyclophosphamide (AC) chemotherapy regimen while simultaneously substantiating the use of trimetazidine as a modifier of the changes induced.Material and Methods. The fundamental, randomized, controlled, experimental in vivo study was conducted. To perform the experimental work, 80 inbred Wistar rats were randomly divided into four groups with equal numbers of animals in each group. The course dosages doxorubicin, cyclophosphamide, and trimetazidine were 15, 150, and 42 mg/kg, respectively. The experiment lasted for 14 days. Trimetazidine was chosen as a probable stabilizer of endothelial functioning.Results. The deviations of the following parameters were evaluated in the framework of this study: total cholesterol, triglycerides, high-density lipoproteins, and low-density lipoproteins. Coronary index and atherogenic index (CA) were also analyzed as prognostic indicators. Statistically significant intergroup differences were recorded in lipid profiles (one-way ANOVA, p < 0.0001) two weeks after beginning the AC chemotherapy regimen. It is worthy of note that the AC chemotherapy regimen caused destabilization of all studied parameters of cholesterol metabolism while trimetazidine showed statistically and pathogenetically significant mild hypolipidemic effect. The study showed that the concentration of CA in group 2 was higher by 187.4 and 172.8%, and the values of coronary risk index (CRI) were higher by 115.8 and 113.9% than the corresponding parameters in groups 1 and 4, respectively. Comparative analysis of groups 3 and 2 showed that the use of TMZ was associated with decreases in CA by 55.5% and in CRI by 44.2% (Tukey’s post-hoc test, p < 0.05).Conclusions. (1) AC chemotherapy regimen was an inducer of atherogenic hyperdyslipidemia, and (2) trimetazidine had a hypolipidemic effect.

show abstract

Section: Adherence To Ethical Standardsunclassified

Trimetazidine as a modifier of doxorubicin+cyclophosphamideinduced hyperdyslipidemia

Avagimyan

Kakturskiy

2022

SJCEM

Self Cite

View full text Add to dashboard Cite

show abstract

“…As a modifi er of chemotherapy-induced CV complications, a well-known and aff ordable piperine-compound myocardial protector TMZ was chosen considering its antioxidant, cytoprotective, antihypoxic, and antianginal properties [14]. The pharmacological action of TMZ is associated with the mitochondrial 3-ketoacyl-CoA thiolase inhibition [15]. It should be noted that experimental animals were administered not a single chemotherapy drug but a full chemotherapy mode.…”

Section:  Introductionmentioning

confidence: 99%

Trimetazidine as a Modifier of Chemotherapy-Induced Endothelium Homeostasis Disturbances

Авагимян¹,

Кактурский²

2022

Кардиология В Беларуси

View full text Add to dashboard Cite

Введение. Настоящее исследование направлено на изучение взаимосвязи между эндотелиальной дисфункцией, кардиотоксичностью АС-режима химиотерапии и триметазидином опосредованной вазопротекции.Цель. Изучить вазотоксический потенциал AC-режима химиотерапии наряду с одновременной оценкой вазопротекторного потенциала триметазидина.Материалы и методы. Проведенное исследование характеризуется как фундаментальное, рандомизированное, контролируемое, экспериментальное, in vivo. С целью проведения экспериментальной работы было задействовано 80 инбредных крыс линии Wistar, которые были рандомно разделены на 4 равные группы. Модель эндотелиальной дисфункции была получена с использованием химиотерапевтического коктейля, состоящего из доксорубицина и циклофосфамида. В качестве вероятного стабилизатора функционирования эндотелия был выбран триметазидин. Курсовая дозировка доксорубицина составила 15 мг/кг, циклофосфамида – 150 мг/кг, а триметазидина – 42 мг/кг. Продолжительность эксперимента – 14 дней.Результаты. В рамках настоящего исследования оценены девиации эндотелина-1, оксида азота, а также факторов адгезии VCAM и ICAM, маркер воспаления – С-реактивный белок. Полученные данные показали, что триметазидин модифицировал усиление эндотелиальной дисфункции.Выводы: 1. АС-режим химиотерапии оказывает выраженное эндотелий-дискоординирующее воздействие. 2. Триметазидин обладает значимым вазопротекторным потенциалом. Introduction. Our research was determined to investigate the link between endothelial dysfunction, AC-mode of chemotherapy and trimetazidine-driven vasoprotection.Purpose. To investigate the AC-mode of chemotherapy-induced endothelium dysfunction and rationality of TMZ prescription.Materials and methods. The conducted study is characterized as a fundamental, randomized, controlled, experimental in vivo study. To carry out the experimental work, 80 inbred Wistar rats were involved, which were randomly divided into 4 equal groups. A model of endothelial dysfunction was generated using a direct combination of doxorubicin and cyclophosphamide. Trimetazidine was used as a probable stabilizer of endothelial activity. Course dose of doxorubicin – 15 mg/kg, course dose of cyclophosphamide – 150 mg/kg, course dose of trimetazidine – 42 mg/kg. The duration of the experiment was 14 days.Results. Within the framework of this study, deviations of endothelin-1, nitric oxide, as well as adhesion factors VCAM and ICAM, and an inflammatory marker, C-reactive protein, were evaluated.Conclusions: 1. AC-mode of chemotherapy provide pronounced endothelium discoordinating impact. 2. TMZ has sufficient vasoprotective properties.

show abstract

Antineoplastics

2022

Reactions Weekly

View full text Add to dashboard Cite

Chemotherapy as a possible trigger for the myocardial lipomatosis development

Cited by 10 publications

References 12 publications

Trimetazidine as a modifier of doxorubicin+cyclophosphamideinduced hyperdyslipidemia

Trimetazidine as a modifier of doxorubicin+cyclophosphamideinduced hyperdyslipidemia

Trimetazidine as a Modifier of Chemotherapy-Induced Endothelium Homeostasis Disturbances

Antineoplastics

Contact Info

Product

Resources

About